Intervention Review

Long-acting beta2-agonists for bronchiectasis

  1. Aziz Sheikh1,*,
  2. Dermot Nolan2,
  3. Michael Greenstone3

Editorial Group: Cochrane Airways Group

Published Online: 23 OCT 2001

Assessed as up-to-date: 9 AUG 2010

DOI: 10.1002/14651858.CD002155


How to Cite

Sheikh A, Nolan D, Greenstone M. Long-acting beta2-agonists for bronchiectasis. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD002155. DOI: 10.1002/14651858.CD002155.

Author Information

  1. 1

    The University of Edinburgh, Centre for Population Health Sciences, Edinburgh, UK

  2. 2

    King's College School of Medicine and Dentistry, Department of General Practice, London, UK

  3. 3

    Castle Hill Hospital, Cottingham, North Humberside, UK

*Aziz Sheikh, Centre for Population Health Sciences, The University of Edinburgh, Medical School, Doorway 3, Teviot Place, Edinburgh, EH8 9AG, UK. Aziz.Sheikh@ed.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 23 OCT 2001

SEARCH

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Background

Symptoms of bronchiectasis include chronic productive cough, wheeze, breathlessness and recurrent infections of the lower respiratory tract. Long-acting bronchodilators are being used more frequently in the management of people with this condition.

Objectives

To determine the effectiveness of long-acting bronchodilators in the management of bronchiectasis that is not due to cystic fibrosis.

Search methods

We searched the Cochrane Airways Group Specialised Register of bronchiectasis trials. The latest searches were carried out in August 2010.

Selection criteria

Randomised controlled trials, with or without masking.

Data collection and analysis

The results of searches were reviewed against pre-specified criteria.

Main results

We were unable to identify any randomised controlled trials investigating the effectiveness of long-acting bronchodilator therapy in the management of bronchiectasis. An update search in August 2010 did not identify any new studies.

Authors' conclusions

Further research is needed to establish if long-acting bronchodilators have a role in the management of people with bronchiectasis.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Long-acting beta2-agonists for bronchiectasis

Long-acting bronchodilators are used in asthma, so may also benefit people with bronchiectasis. However, there is no good evidence for this at present.

 

摘要

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

背景

以長效支氣管擴張劑(Longacting beta2agonists)來治療支氣管擴張症(bronchiectasis)

支氣管擴張症的症狀包括慢性咳嗽,氣喘,呼吸困難和經常性的下呼吸道感染。目前長效支氣管擴張劑(Longacting bronchodilators)經常被用來管理這樣的情況。

目標

探討長效支氣管擴張劑對管對非囊腫性纖維化(Cystic fibrosis)支氣管擴張症的效用。

搜尋策略

我們搜尋了支氣管擴張臨床試驗的專門登錄資料庫。搜尋更新到2008年8月。

選擇標準

隨機對照試驗,無論雙盲(masking)與否。

資料收集與分析

我們將搜查的結果跟預先決定的標準比較。

主要結論

我們無法找出任何調查以長效支氣管擴張劑治療支氣管擴張症效果的隨機對照試驗在2006年8月的更新搜索沒有發現任何新的研究。

作者結論

我們需要更多的研究來以確定是否長效支氣管擴張劑在管理支氣管擴張症上有效。

翻譯人

本摘要由臺北醫學大學萬芳醫院楊璧如翻譯。

此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。

總結

長效支氣管擴張劑被用來治療氣喘,所以有可能對支氣管擴張症有效。然而,目前沒有足夠的證據支持這個推論。